Sugi Predict

Sugi Predict / Targets / VSIG8

VSIG8

V-set and immunoglobulin domain-containing protein 8 · P0DPA2 · VSIG8 on Sugi Atlas →

30 patent compounds predicted against VSIG8, 16 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1881761 SCHEMBL1881761 0.46 1/20
SCHEMBL4348744 SCHEMBL4348744 0.46 1/20
SCHEMBL27075633 SCHEMBL27075633 0.46 1/20
SCHEMBL23831902 SCHEMBL23831902 0.44 1/20
SCHEMBL30105137 SCHEMBL30105137 0.44 1/20
SCHEMBL29556191 SCHEMBL29556191 0.43 1/20
SCHEMBL6824382 SCHEMBL6824382 0.42 1/20
SCHEMBL23831786 SCHEMBL23831786 0.42 1/20
SCHEMBL23831985 SCHEMBL23831985 0.42 1/20
SCHEMBL30105147 SCHEMBL30105147 0.42 1/20
SCHEMBL30105316 SCHEMBL30105316 0.42 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7736206) 0.42 1/20
SCHEMBL23832101 SCHEMBL23832101 0.41 1/20
SCHEMBL30105022 SCHEMBL30105022 0.41 1/20
SCHEMBL27568334 SCHEMBL27568334 0.41 1/20
SCHEMBL16813039 SCHEMBL16813039 0.40 1/20

Clinical trials — most relevant to VSIG8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency PHASE3RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine PHASE1/PHASE2UNKNOWN
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine PHASE1COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors nanNOT_YET_RECRUITING
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection nanUNKNOWN
Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA nanCOMPLETED
Molecular Profile of the Evolution of Inclusion Body Myositis nanCOMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy nanRECRUITING
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry nanUNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Risk Factors for the Development of Celiac Disease in Genetically Predisposed Children nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis nanUNKNOWN
Developing Newborn Screening for Infants With Primary Immunodeficiency nanCOMPLETED
Gene Expression in Inflammatory Bowel Disease nanENROLLING_BY_INVITATION
Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer nanUNKNOWN
Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19) nanRECRUITING
Perioperative Plasma Levels of Glycocalyx Markers in Colon Surgery. nanUNKNOWN
Efferocytosis and Genomic Polymorphism in Autoimmune Diseases nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a VSIG8 binder may also engage these)

ProteinNameSimilarity
Q6P3A4 — 0.998 Q6P3A4 →
Q8BR86 — 0.979 Q8BR86 →
Q8IZU9 — 0.979 Q8IZU9 →
Q62925 — 0.976 Q62925 →
Q68FM6 — 0.972 Q68FM6 →
Q62136 — 0.971 Q62136 →
Q9JKF6 — 0.971 Q9JKF6 →
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 0.970 landscape →
Q9BE71 — 0.969 Q9BE71 →
Q58EG3 — 0.969 Q58EG3 →
O75129 — 0.968 O75129 →
Q6NS60 — 0.967 Q6NS60 →
Q80TG9 — 0.967 Q80TG9 →
Q6RKD8 — 0.967 Q6RKD8 →
Q60805 — 0.966 Q60805 →
Q460M5 — 0.966 Q460M5 →
Q9WU40 — 0.966 Q9WU40 →
Q6PFH3 — 0.966 Q6PFH3 →
Q9GL76 — 0.966 Q9GL76 →
Q05909 — 0.966 Q05909 →
O14525 — 0.965 O14525 →
Q5R3F8 — 0.965 Q5R3F8 →
Q80U40 — 0.965 Q80U40 →
Q9R1K2 — 0.965 Q9R1K2 →
A2CIR7 — 0.965 A2CIR7 →
Q8K099 — 0.965 Q8K099 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.964 landscape →
Q15223 — 0.964 Q15223 →
Q9WTR8 — 0.964 Q9WTR8 →
Q9UPU7 — 0.964 Q9UPU7 →